Little Rock, Arkansas 72205


The purpose of this study is to evaluate the clinical efficacy of an investigational agent, P10s-PADRE, a peptide mimotope-based vaccine, in patients of all races with stage IV Non-Small Cell Lung Cancer who have completed their primary chemotherapy without progressing, and who still have measurable residual disease. A randomized double-blind placebo-controlled trial is designed with the goal being to evaluate the efficacy of the vaccine. Efficacy will be based primarily on the tumor response, and secondarily on progression-free survival. Information on safety and tolerability will be collected. Humoral and cellular immune responses will be analyzed.


Inclusion Criteria: - stage IV Non-Small Cell Lung Cancer - completed their primary chemotherapy - achieved either stable disease or partial response with measurable residual disease Exclusion Criteria: - Women who are pregnant or breast-feeding. - Patients who have autoimmune disease or are immunosuppressed or receiving systemic corticosteroids



Primary Contact:

Principal Investigator
Konstantinos Arnaoutakis, MD
University of Arkansas

Konstantinos Arnaoutakis, MD

Backup Contact:


Location Contact:

Little Rock, Arkansas 72205
United States

Konstantinos Arnaoutakis, MD

Site Status: Recruiting

Data Source:

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.